Posted by Michael Wonder on 23 May 2023
Lumicell announces FDA acceptance and priority review of new drug application for Lumisight optical imaging agent for breast cancer
22 May 2023 - The system visually highlights cancer that may have otherwise been left behind and is designed to be an adjunct to standard of care.
Lumicell today announced the US FDA has accepted and granted priority review for the new drug application for the Lumisight Optical Imaging Agent and accepted the premarket approval application for the Lumicell direct visualization system.
